{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:31:26Z","timestamp":1783470686435,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jfo.2024.104234","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:24:58Z","timestamp":1718324698000},"page":"104234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["R\u00e9sultats anatomiques et fonctionnels du protocole th\u00e9rapeutique \u00ab\u00a03 + PRN\u00a0\u00bb dans le traitement de l\u2019\u0153d\u00e8me maculaire diab\u00e9tique"],"prefix":"10.1016","volume":"47","author":[{"given":"W.","family":"Ammari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Chaabene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Messaoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2024.104234_bib0275","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ophtha.2021.07.009","article-title":"Intravitreal pharmacotherapies for diabetic macular edema","volume":"129","author":"Ehlers","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104234_bib0280","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104234_bib0285","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbrc.2011.04.014","article-title":"Comparing protein VEGF inhibitors: in vitro biological studies","volume":"408","author":"Yu","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jfo.2024.104234_bib0290","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11912-013-0368-7","article-title":"Aflibercept\u00a0\u2013\u00a0a decoy VEGF receptor","volume":"16","author":"Ciombor","year":"2014","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jfo.2024.104234_bib0295","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jamaophthalmol.2015.4636","article-title":"Effect of ranibizumab on the decision to drive and vision function relevant to driving in patients with diabetic macular edema: report from RESTORE, RIDE, and RISE trials","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0300","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00417-018-04213-x","article-title":"Efficacy and safety of ranibizumab 0.5\u00a0mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study","volume":"257","author":"Li","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0305","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa2204225","article-title":"Aflibercept monotherapy or bevacizumab first for diabetic macular edema","volume":"387","author":"Jhaveri","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2024.104234_bib0310","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104234_bib0315","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","article-title":"Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema","volume":"28","author":"Cai","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0320","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.3390\/ijms23169424","article-title":"Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review","volume":"23","author":"Liberski","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jfo.2024.104234_bib0325","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/pharmaceutics15051413","article-title":"Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration","volume":"15","author":"Desideri","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jfo.2024.104234_bib0330","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs. laser photocoagulation vs. observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jfo.2024.104234_bib0335","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104234_bib0340","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/IAE.0000000000002302","article-title":"Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR.net Protocol I 5-Year Report","volume":"38","author":"Bressler","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104234_bib0345","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000502779","article-title":"The Diabetic Retinopathy Clinical Research Network (DRCR.net) and its contributions to the treatment of diabetic retinopathy","volume":"62","author":"Sun","year":"2019","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jfo.2024.104234_bib0350","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104234_bib0355","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","article-title":"Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema","volume":"136","author":"Maturi","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0360","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3928\/23258160-20140306-08","article-title":"Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents","volume":"45","author":"Fileta","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"10.1016\/j.jfo.2024.104234_bib0365","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/1120672120902028","article-title":"Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis","volume":"31","author":"Torres-Costa","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0370","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00417-018-04213-x","article-title":"Efficacy and safety of ranibizumab 0.5\u00a0mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study","volume":"257","author":"Li","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0375","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","article-title":"Diabetic macular edema: pathophysiology and novel therapeutic targets","volume":"122","author":"Das","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104234_bib0380","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2014.09.033","article-title":"Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema","volume":"159","author":"Rayess","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0385","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/IAE.0000000000001645","article-title":"Changes in central choroidal thickness after treatment of diabetic macular edema with intravitreal bevacizumab correlation with central macular thickness and best-corrected visual acuity","volume":"38","author":"Nourinia","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104234_bib0390","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00417-018-4072-z","article-title":"Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema","volume":"256","author":"Campos","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0395","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/jop.2018.0082","article-title":"Outcome and predictors for 2-year visual acuity in eyes with diabetic macular edema treated with ranibizumab","volume":"35","author":"Eski Yucel","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2024.104234_bib0400","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ophtha.2015.02.036","article-title":"Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab","volume":"122","author":"Sophie","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104234_bib0405","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/eye.2013.245","article-title":"Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab","volume":"28","author":"Channa","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfo.2024.104234_bib0410","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104234_bib0415","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/IAE.0b013e3181c2e0d6","article-title":"Correlation between visual acuity and foveal microstructural changes in diabetic macular edema","volume":"30","author":"Otani","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104234_bib0420","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/APO.0000000000000468","article-title":"Optical coherence tomography classification systems for diabetic macular edema and their associations with visual outcome and treatment responses\u00a0\u2013\u00a0An updated review","volume":"11","author":"Hui","year":"2021","journal-title":"Asia-Pac J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0425","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajo.2010.01.039","article-title":"The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema","volume":"150","author":"Maheshwary","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0430","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/bjophthalmol-2021-319587","article-title":"OCT-based biomarkers for predicting treatment response in eyes with center-involved diabetic macular edema treated with anti-VEGF injections: a real-life retina clinic-based study","volume":"107","author":"Szeto","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0435","doi-asserted-by":"crossref","first-page":"39161","DOI":"10.1038\/srep39161","article-title":"Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema","volume":"6","author":"Mori","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfo.2024.104234_bib0440","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000330045","article-title":"Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema","volume":"226","author":"Kim","year":"2011","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jfo.2024.104234_bib0445","doi-asserted-by":"crossref","first-page":"149","DOI":"10.29271\/jcpsp.2020.02.149","article-title":"Effect of optical coherence tomography patterns on one-year outcomes of aflibercept therapy for diabetic macular edema","volume":"30","author":"Ozcaliskan","year":"2020","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.jfo.2024.104234_bib0450","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/IAE.0b013e31826b6763","article-title":"Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema","volume":"33","author":"Shimura","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104234_bib0455","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1136\/bjophthalmol-2016-308388","article-title":"Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature","volume":"100","author":"Ashraf","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0460","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ophtha.2017.08.031","article-title":"OCT Biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant","volume":"125","author":"Zur","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104234_bib0465","doi-asserted-by":"crossref","first-page":"373","DOI":"10.5935\/0004-2749.20160106","article-title":"Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema","volume":"79","author":"Ercalik","year":"2016","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0470","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000524742","article-title":"Epiretinal membrane in patients with diabetic macular edema","volume":"245","author":"Rabina","year":"2022","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jfo.2024.104234_bib0475","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ajo.2007.07.012","article-title":"Optical coherence tomography findings in persistent diabetic macular edema: the vitreomacular interface","volume":"144","author":"Ghazi","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0480","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ajo.2018.04.010","article-title":"Vision outcomes following anti-vascular endothelial growth factor treatment of diabetic macular edema in clinical practice","volume":"191","author":"Holekamp","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0485","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","article-title":"Ranibizumab 0.5\u00a0mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study","volume":"100","author":"Prunte","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0490","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2019.02.005","article-title":"Randomized trial of treat and extend ranibizumab with and without navigated laser versus monthly dosing for diabetic macular edema: TREX-DME 2-year outcomes","volume":"202","author":"Payne","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0495","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.3928\/23258160-20181101-17","article-title":"Monthly versus treat-and-extend ranibizumab for diabetic macular edema: a prospective, randomized trial","volume":"49","author":"Eichenbaum","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jfo.2024.104234_bib0500","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0974-9233.172293","article-title":"Updates on the clinical trials in diabetic macular edema","volume":"23","author":"Demirel","year":"2016","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0505","first-page":"200","article-title":"Visual outcomes following intravitreal ranibizumab for diabetic macular edema in a pro re nata protocol from baseline: a real-world experience","volume":"8","author":"James","year":"2019","journal-title":"Asia Pac J Ophthalmol(Phila)"},{"key":"10.1016\/j.jfo.2024.104234_bib0510","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12886-020-01510-0","article-title":"Anatomical and functional responses in eyes with diabetic macular edema treated with \u201c1\u00a0+\u00a0PRN\u201d ranibizumab: one-year outcomes in a population of mainland China","volume":"20","author":"Lai","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0515","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intra vitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104234_bib0520","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40942-016-0041-z","article-title":"Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data","volume":"2","author":"Ziemssen","year":"2016","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.jfo.2024.104234_bib0525","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5935\/0004-2749.20200078","article-title":"Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results","volume":"83","author":"Cakir","year":"2020","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0530","first-page":"18","article-title":"Cost-effectiveness","volume":"160","author":"Pershing","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfo.2024.104234_bib0535","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.2147\/OPTH.S317771","article-title":"Efficacy and cost-effectiveness of anti-VEGF for treating diabetic retinopathy in the Indian population","volume":"15","author":"Pramanik","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104234_bib0270","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12886-020-01637-0","article-title":"Cost consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients","volume":"20","author":"Ruiz-Moreno","year":"2020","journal-title":"BMC Ophthalmol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224001797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224001797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T15:22:55Z","timestamp":1726154575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551224001797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0181551224001797"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104234","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"R\u00e9sultats anatomiques et fonctionnels du protocole th\u00e9rapeutique \u00ab\u00a03+PRN\u00a0\u00bb dans le traitement de l\u2019\u0153d\u00e8me maculaire diab\u00e9tique","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104234"}}